Kaplan-Meier plots of adverse effect (OS and EFS) of RUNX1 mutations. (A) Patients with intermediate cytogenetic risk without mutations in NPM1, CEBPA, FLT3-ITD, or MLL-PTD. (B) No effect of RUNX1 mutations in patients with high-risk FLT3-ITD– or MLL-PTD–positive AML; n.r. indicates not reached.